Immunovant, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMVT Nasdaq 2836 immunovant.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunovant, Inc.

Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Jan 12th, 2026 8:11 am
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - Dec 18th, 2025 12:55 am
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - Dec 17th, 2025 7:45 am
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse - Dec 15th, 2025 2:28 pm
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? - Dec 15th, 2025 12:09 pm
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday as Oracle Results Sour Investor Mood - Dec 11th, 2025 6:54 am
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day - Dec 11th, 2025 5:30 am
Immunovant Announces Pricing of $550 Million Common Stock Financing - Dec 10th, 2025 11:29 pm
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Dec 10th, 2025 9:30 am
Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Dec 2nd, 2025 8:15 pm
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - Nov 29th, 2025 11:29 am
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - Nov 11th, 2025 10:52 am
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update - Nov 10th, 2025 5:00 am
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 - Nov 10th, 2025 5:00 am
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Nov 2nd, 2025 10:08 pm
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - Oct 31st, 2025 8:03 am
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Oct 27th, 2025 2:10 pm
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - Oct 7th, 2025 10:57 pm
Where is Immunovant (IMVT) Heading According to Analysts? - Sep 30th, 2025 2:00 am
Roivant Sciences (ROIV) Is Up 9.4% After Positive Immunovant Data and Japan Orphan Drug Nod - What's Changed - Sep 11th, 2025 5:46 am